Cybin Inc., a biopharmaceutical company based in Ontario, Canada, has filed a post-effective amendment with the U.S. Securities and Exchange Commission (SEC) on April 10, 2024. This amendment modifies the company's previous Form F-10 registration statement by including the potential offering and issuance of securities to various selling securityholders. The amendment, identified as Amendment No. 1, updates the short form base shelf prospectus originally dated August 17, 2023, and subsequently amended on December 22, 2023. Cybin Inc. has outlined that the securities may be offered from time to time after the registration statement becomes effective, with the offerings potentially including common shares, warrants, units, debt securities, and subscription receipts totaling up to $400 million. The amendment also details the conditions under which the securities may...Show More

Cybin Inc., a biopharmaceutical company based in Ontario, Canada, has filed a post-effective amendment with the U.S. Securities and Exchange Commission (SEC) on April 10, 2024. This amendment modifies the company's previous Form F-10 registration statement by including the potential offering and issuance of securities to various selling securityholders. The amendment, identified as Amendment No. 1, updates the short form base shelf prospectus originally dated August 17, 2023, and subsequently amended on December 22, 2023. Cybin Inc. has outlined that the securities may be offered from time to time after the registration statement becomes effective, with the offerings potentially including common shares, warrants, units, debt securities, and subscription receipts totaling up to $400 million. The amendment also details the conditions under which the securities may be sold, including the possibility of 'at-the-market' distributions. The company has clarified that no proceeds from the sale of securities by selling securityholders will be received by Cybin Inc. This filing allows Cybin to make securities available for sale through a streamlined process and provides flexibility in financing options for the company's future growth and development.